Pending FDA's OK, Teva and Alvotech can bring their Stelara biosimilar to US market by 2025
Alvotech and partner Teva have now conquered half the hurdle in bringing a Stelara biosimilar to market.
The two companies announced Monday that they agreed to a settlement and license agreement with Johnson & Johnson to bring candidate AVT04 to US consumers by no later than Feb. 21, 2025.
A Janssen representative told Endpoints News in an email on Monday that the terms of the agreement are confidential, adding that the company “will continue to defend the intellectual property associated with our medicines to protect our ability to innovate and develop life-changing therapies for patients.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.